Aytu BioScience (NASDAQ:AYTU) has begun shipping its rapid antibody blood test for COVID-19. Shares up 8% premarket.
Stryker (NYSE:SYK) has developed
a low-cost limited-release emergency response bed for healthcare
providers during the pandemic. It anticipates being able to produce 10K
beds per week.
Novartis (NYSE:NVS) and the Novartis US Foundation have established a
US COVID-19 Community Response Fund that will provide $5M in cash and
in-kind donations for immediate response and recovery efforts.
ResTORbio (NASDAQ:TORC) has postponed enrollment
in the fifth cohort in its ongoing New Zealand-based Phase 1b/2a
clinical trial of RTB101 in Parkinson’s due to level 4 alert there.
Capricor Therapeutics (NASDAQ:CAPR) will provide its CAP-1002 cell therapy under compassionate use for patients with advanced COVID-19. Shares up 34% premarket.
I-Mab (NASDAQ:IMAB) announced FDA
sign-off on its IND for a clinical trial evaluating TJM2 for the
treatment of cytokine release syndrome in severely ill COVID-19
patients. Shares up 9% premarket.
https://seekingalpha.com/news/3558148-shipping-begins-for-rapid-antibody-test-covidminus-19-updates
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.